A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Docetaxel
  • Indications Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RANGE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Sep 2017 Results of the primary analysis (Data cut off: April 21, 2017) published in The Lancet.
    • 10 Sep 2017 Results from this trial will be published in The Lancet, according to an Eli Lilly media release.
    • 10 Sep 2017 Results from this trial have been presented at ESMO 2017 Congress Presidential Symposium and published in The Lancet, according to an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top